Intuitive Surgical (NASDAQ:ISRG) VP Sells $1,834,140.87 in Stock

Intuitive Surgical, Inc. (NASDAQ:ISRG) VP Fredrik Widman sold 4,047 shares of Intuitive Surgical stock in a transaction on Friday, October 23rd. The stock was sold at an average price of $453.21, for a total value of $1,834,140.87. Following the transaction, the vice president owned 1,026 shares in the company, valued at approximately $464,993.46. This represents a 79.78% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Fredrik Widman also recently made the following trade(s):

• On Tuesday, September 15th, Fredrik Widman sold 1,089 shares of Intuitive Surgical stock. The shares were sold at an average price of $374.44, for a total transaction of $407,765.16.

Intuitive Surgical Trading Down 0.1%

Intuitive Surgical stock traded down $0.66 during midday trading on Monday, hitting $451.63. 2,916,696 shares of the stock were exchanged, compared to its average volume of 2,433,892. The stock’s 50-day simple moving average is $395.50 and its 200 day simple moving average is $408.83. Intuitive Surgical, Inc. has a fifty-two week low of $328.57 and a fifty-two week high of $603.88. The stock has a market capitalization of $156.55 billion, a price-to-earnings ratio of 54.61, a PEG ratio of 3.12 and a beta of 1.46.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings results on Tuesday, October 20th. The medical equipment provider reported $3.00 earnings per share for the quarter, beating the consensus estimate of $2.65 by $0.35. The business had revenue of $3.05 billion during the quarter, compared to analysts’ expectations of $2.91 billion. Intuitive Surgical had a net margin of 25.54% and a return on equity of 18.17%. The business’s revenue for the quarter was up 21.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.40 EPS. Equities analysts anticipate that Intuitive Surgical, Inc. will post 9.37 EPS for the current fiscal year.

Key Stories Impacting Intuitive Surgical

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Analysts and market commentators continue to view Intuitive Surgical as a strong growth company, citing durable demand for robotic-assisted surgery and potential for the stock to outperform the broader market. Intuitive Surgical Is an Incredible Growth Stock: 3 Reasons Why
• Positive Sentiment: Higher earnings estimates are providing a near-term bullish catalyst. The revisions suggest analysts are becoming more optimistic about ISRG’s financial outlook, potentially supporting further gains. Earnings Estimates Moving Higher for Intuitive Surgical
• Neutral Sentiment: ISRG is receiving elevated investor attention across financial websites, but the “trending stock” coverage is primarily informational rather than a new business or earnings announcement. Intuitive Surgical Is a Trending Stock: Facts to Know Before Betting on It
• Neutral Sentiment: Commentary is also addressing whether Intuitive Surgical’s premium valuation is justified. This may keep investors selective even as the company’s long-term growth story remains intact. If Intuitive Surgical Stock Looks Expensive, You Need To Read This
• Negative Sentiment: Director Gary Guthart sold 20,095 shares for approximately $9.1 million, reducing his direct ownership by 1.64%. Because the sale was made under a pre-arranged Rule 10b5-1 plan, it may not reflect a change in the company’s outlook, but insider selling can still weigh on sentiment. SEC Insider Transaction Filing

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. North Point Portfolio Managers Corp OH acquired a new stake in Intuitive Surgical in the third quarter valued at $27,000. Compass Wealth Management LLC purchased a new position in shares of Intuitive Surgical in the 3rd quarter valued at about $29,000. Main Street Group LTD purchased a new position in shares of Intuitive Surgical in the 1st quarter valued at about $30,000. Compass Financial Management LLC purchased a new position in shares of Intuitive Surgical in the 2nd quarter valued at about $30,000. Finally, Evergreen Advisors LLC acquired a new stake in shares of Intuitive Surgical during the 1st quarter worth about $35,000. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on ISRG shares. Oppenheimer reiterated an “outperform” rating and issued a $500.00 price objective on shares of Intuitive Surgical in a report on Wednesday, October 21st. BTIG Research restated a “buy” rating and set a $454.00 target price on shares of Intuitive Surgical in a report on Wednesday, October 21st. Mizuho dropped their target price on Intuitive Surgical from $415.00 to $400.00 and set a “neutral” rating for the company in a research report on Wednesday, October 21st. Barclays reaffirmed an “overweight” rating and issued a $500.00 target price (up from $485.00) on shares of Intuitive Surgical in a research report on Wednesday, October 21st. Finally, Erste Group Bank raised shares of Intuitive Surgical from a “hold” rating to a “buy” rating in a research report on Wednesday, October 21st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $493.54.

About Intuitive Surgical

Intuitive Surgical, Inc develops and manufactures robotic-assisted systems and related technologies for minimally invasive surgery. Its products are designed to help surgeons perform procedures through small incisions while providing enhanced visualization, precision and control. The company’s primary platform is the da Vinci Surgical System, which is used across a range of specialties, including urology, gynecology, general surgery, cardiothoracic surgery and other procedures.

The company also offers the Ion endoluminal system, which is designed to support minimally invasive lung biopsy procedures.